Difference between revisions of "CH Basel Balavenkatraman KK"
From Bioblast
Nirschl Lisa (talk | contribs) |
Beno Marija (talk | contribs) |
||
| Line 6: | Line 6: | ||
|country=Switzerland | |country=Switzerland | ||
|Contact=Balavenkatraman Kamal Kumar | |Contact=Balavenkatraman Kamal Kumar | ||
|MiPNetLab=Grueninger Stephan | |MiPNetLab=Grueninger Stephan | ||
|Team previous=Chiesi Michele | |Team previous=Chiesi Michele, Weiss Alexander | ||
|Status=O2k 2007 – | |Status=O2k 2007 – | ||
|info=[[IOC106]], [[IOC39]] | |info=[[IOC106]], [[IOC39]] | ||
Latest revision as of 11:39, 14 May 2019
CH Basel Balavenkatraman KK
| O2k-Network Lab | Investigator II (iTox-PCS) - Novartis Pharma Ltd., WKL-135.3.21 |
|---|---|
| Address | Klybeckstr 191, 4057 |
| City | Basel |
| State/Prov | |
| Country | Switzerland |
| Weblink | |
| Contact | Balavenkatraman Kamal Kumar |
| Team | Grueninger Stephan |
| Team previous | Chiesi Michele, Weiss Alexander |
| Status | O2k 2007 – |
| Oroboros Events | IOC106, IOC39 |
| Topics |
O2k-Publications
update please
O2k-Abstracts
update please
- Previously CH_Basel_Chiesi M
